Novartis presented updated Phase III NATALEE trial results at ESMO 2024, showing that Kisqali (ribociclib) with endocrine ...
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...
Vadodara: Alembic Pharma has announced that Sudhakar Pandiyan has been appointed as Head - Technical Operations (Sterile & ...
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over ...
NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...
Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...
In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...
With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...
Livewire Markets on MSN2d
The 7 biotech stocks (and their trials) these experts are watching right nowDr Bianca Ogden and Hashan De Silva share the companies and trials they find interesting in the constantly innovating biotech ...
whilst growing its pipeline with other deals such as a $1.75 billion offer for Mariana Oncology in May that has yet to complete. Lutathera made $605 million in sales last year, but Novartis ...
Inc. and Novartis Oncology. Earlier in his career he served with McKinsey & Company, where he strategically advised clients in the pharmaceutical industry. Dr. Will received his Medical Degree from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback